Table 2.
Univariable and multivariable analysis of clinicopathological and molecular features in high-risk endometrial cancer patients.
| Recurrence | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| n = 643, 207 events | HR | 95% CI | p-value | HR | 95% CI | p-value |
| Age | ||||||
| ≤60 years | 1 | 1 | ||||
| >60 years | 1.97 | 1.43–2.72 | <.001 | 1.43 | 1.02–2.01 | 0.037 |
| Stage | ||||||
| I | 1 | 1 | ||||
| II | 1.09 | 0.74–1.63 | 0.66 | 1.78 | 1.15–2.75 | 0.009 |
| III | 2.14 | 1.52–3.00 | <.001 | 3.47 | 2.37–5.07 | <.001 |
| Histology and grade | ||||||
| Endometrioid, low-grade | 1 | 1 | ||||
| Endometrioid, high-grade | 1.12 | 0.79–1.60 | 0.52 | 1.48 | 0.98–2.23 | 0.06 |
| Non-endometrioid | 1.60 | 1.16–2.19 | 0.004 | 1.47 | 0.96–2.26 | 0.08 |
| LVSI | ||||||
| Absent | 1 | 1 | ||||
| Present | 1.53 | 1.13–2.06 | 0.006 | 1.32 | 0.97–1.79 | 0.08 |
| Treatment received | ||||||
| RT (VBT or EBRT) | 1 | 1 | ||||
| RT (VBT or EBRT) + CT | 0.81 | 0.58–1.13 | 0.21 | 0.65 | 0.47–0.91 | 0.012 |
| Molecular subgroups | ||||||
| MMRd | 1 | 1 | ||||
| POLEmut | 0.09 | 0.02–0.38 | 0.001 | 0.11 | 0.03–0.46 | 0.002 |
| NSMP | 1.00 | 0.70–1.43 | 0.99 | 0.97 | 0.66–1.42 | 0.87 |
| p53abn | 2.30 | 1.65–3.21 | <.001 | 2.43 | 1.65–3.57 | <.001 |
Model fit multivariable model: Akaike’s information criterion (AIC) 2173.77, model concordance (C-index) 0.712. Bootstrap resampling model validation: C-index re-estimation 0.72.
HR hazard ratio, CI confidence interval, LVSI lymphovascular space invasion, RT radiotherapy, VBT vaginal brachytherapy, EBRT external beam radiotherapy, CT chemotherapy, MMRd mismatch repair-deficient, POLEmut POLE ultra-mutated, p53abn p53-abnormal, NSMP no specific molecular profile, IHC immunohistochemistry.